Image Al Dia News

New Vaccine Developed in Argentina Helps Combat Pneumonia

Through a strategic alliance with Pfizer, Argentina strengthens its healthcare capabilities and positions itself as a regional leader in manufacturing.

MÁS EN ESTA SECCIÓN

¡Urgente! Escasez de Sangre

Argentina se Retira de OMS

Riñones de Cerdo en Humanos

US$100.000 millones de Bill

Dia Mundial del Cáncer

Vacuna para la Obesidad

COMPARTA ESTE CONTENIDO:

Argentina Advances in Vaccine Production: The Local Manufacturing of the 20-Valent Pneumococcal Vaccine

Argentina has taken a significant step in local production of the 20-valent conjugate pneumococcal vaccine (VCN20), establishing itself as a regional leader in Latin America and joining the select group of nations capable of manufacturing and exporting life-saving vaccines. This achievement stems from a strategic technology transfer partnership between global pharmaceutical giant Pfizer and local biotech company Sinergium Biotech. 

The 20-Valent Conjugate Pneumococcal Vaccine (VCN20)

VCN20 is an innovative vaccine designed to protect against 20 serotypes of Streptococcus pneumoniae, the bacteria responsible for severe diseases such as pneumonia, meningitis, and sepsis in children and adults. The Argentine National Administration of Drugs, Food, and Medical Technology (ANMAT) approved its use for the prevention of these diseases in infants, children, adolescents, and adults. 

Technology Transfer and Local Production

The collaboration between Pfizer and Sinergium Biotech involves transferring the necessary technology for VCN20 production in Argentina. This agreement enables the country to not only meet its domestic demand but also become an export hub for the region, strengthening Latin America’s healthcare capabilities. 

Impact on Public Health and the Economy

The local production of VCN20 has multiple benefits:

  • Improved Public Health: Ensures a steady and accessible supply of vaccines critical for preventing pneumococcal diseases and reducing associated mortality.
  • Economic Development: Boosts the national biotech industry, creates jobs, and positions Argentina as a key player in vaccine production in the region.
  • Health Sovereignty: Reduces reliance on imports, granting greater autonomy in public health policy management.

Comparison with Regional Initiatives

Argentina is not the only country in the region advancing in vaccine production. Brazil, through the Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), has also been selected to develop and produce vaccines using messenger RNA technology. These initiatives highlight a collective effort in Latin America to enhance vaccine production capacity and improve equitable access across the region. 

Challenges and Future Perspectives

Despite the progress, local vaccine production faces challenges such as the need for adequate infrastructure, training specialized personnel, and meeting international quality standards. However, the experience gained and strategic partnerships place Argentina on a promising path toward self-sufficiency in vaccine production and significant contributions to public health in the region.

Conclusion

The local production of the 20-valent conjugate pneumococcal vaccine in Argentina, resulting from the collaboration between Pfizer and Sinergium Biotech, marks a milestone in the country’s biotech industry. This achievement not only strengthens national healthcare capabilities but also positions Argentina as a leader in vaccine production and exportation in Latin America, contributing to the well-being and health of millions across the region.